AstraZeneca

AstraZeneca

AstraZenecaAstraZeneca is a major international healthcare business engaged in research, development, manufacturing and marketing of prescription pharmaceuticals and supplier for healthcare services. AstraZeneca is one of the world's leading pharmaceutical companies with healthcare sales of US $29.55 billion and is a leader in gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infection product sales. AstraZeneca is listed in the Dow Jones Sustainability Index (Global) as well as the FTSE4Good Index. For more information visit www.astrazeneca.com.

AstraZeneca RSS Channel

Filters
List of articles in category AstraZeneca
Title Published Date
AstraZeneca advances response to global COVID-19 challenge as it receives first commitments for Oxford's potential new vaccine 22 May 2020
AstraZeneca and Oxford University announce landmark agreement for COVID-19 vaccine 30 April 2020
AstraZeneca and Saint Luke’s Mid America Heart Institute initiate Phase III DARE-19 trial with Farxiga in COVID-19 patients 24 April 2020
AstraZeneca initiates CALAVI clinical trial with Calquence against COVID-19 16 April 2020
AstraZeneca to donate 9 million face masks to support healthcare workers around the world in the fight against COVID-19 25 March 2020
AstraZeneca completes divestment agreement with Atnahs Pharma for established hypertension medicines 03 March 2020
AstraZeneca divests rights to established hypertension medicines 28 January 2020
AstraZeneca divests rights to Seroquel and Seroquel XR in Europe and Russia 30 October 2019
AstraZeneca divests rights for Losec to Cheplapharm 01 October 2019
AstraZeneca amends collaboration with Ironwood for Linzess in China 20 September 2019
Farxiga met primary endpoint in landmark Phase III DAPA-HF trial for the treatment of patients with heart failure 20 August 2019
New data show Symbicort reduces attacks in mild asthma when used as an anti-inflammatory reliever 23 May 2019
Trastuzumab deruxtecan demonstrated clinically-meaningful response in patients with refractory HER2-positive metastatic breast cancer 09 May 2019
AstraZeneca starts artificial intelligence collaboration to accelerate drug discovery 30 April 2019
Brilinta’s Phase III THEMIS trial met primary endpoint in 
patients with established coronary artery disease and type-2 diabetes 26 February 2019
Forxiga receives positive EU CHMP opinion for the treatment of adults with type-1 diabetes 04 February 2019
AstraZeneca announces organisational changes 07 January 2019
AstraZeneca and Cancer Research UK launch Functional Genomics Centre to accelerate the discovery of new medicines 10 December 2018
Agreement with Grünenthal for rights to Nexium in Europe and Vimovo worldwide (ex-US) 30 October 2018
AstraZeneca strengthens and expands oncology development and commercialisation collaboration with Innate Pharma 26 October 2018
p372_300x250 Richard